Fluidigm (FLDM) Rating Increased to Overweight at Piper Jaffray Companies

Fluidigm (NASDAQ:FLDM) was upgraded by equities researchers at Piper Jaffray Companies from a “neutral” rating to an “overweight” rating in a research report issued on Friday, Marketbeat.com reports.

Several other research analysts have also weighed in on FLDM. Zacks Investment Research raised shares of Fluidigm from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. BidaskClub raised shares of Fluidigm from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th.

FLDM stock traded up $0.17 during mid-day trading on Friday, hitting $7.35. 877,422 shares of the company were exchanged, compared to its average volume of 200,501. The company has a quick ratio of 1.64, a current ratio of 2.05 and a debt-to-equity ratio of 4.79. Fluidigm has a 12-month low of $4.45 and a 12-month high of $8.62.

Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, November 1st. The medical research company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.20). The company had revenue of $28.96 million for the quarter, compared to analysts’ expectations of $27.50 million. Fluidigm had a negative return on equity of 77.14% and a negative net margin of 50.46%. As a group, analysts expect that Fluidigm will post -0.99 EPS for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. acquired 34,896 shares of the stock in a transaction dated Tuesday, October 9th. The stock was acquired at an average price of $7.29 per share, with a total value of $254,391.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders bought 98,951 shares of company stock valued at $715,224. Insiders own 2.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in shares of Fluidigm by 64.8% in the first quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock valued at $169,000 after purchasing an additional 11,377 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of Fluidigm by 9.9% in the second quarter. Perkins Capital Management Inc. now owns 169,000 shares of the medical research company’s stock valued at $1,007,000 after purchasing an additional 15,250 shares during the period. LMR Partners LLP purchased a new position in shares of Fluidigm in the second quarter valued at approximately $144,000. BlackRock Inc. boosted its stake in shares of Fluidigm by 1.3% in the first quarter. BlackRock Inc. now owns 2,212,763 shares of the medical research company’s stock valued at $12,923,000 after purchasing an additional 27,881 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of Fluidigm by 70.8% in the second quarter. Jennison Associates LLC now owns 68,791 shares of the medical research company’s stock valued at $410,000 after purchasing an additional 28,520 shares during the period. 96.87% of the stock is owned by institutional investors and hedge funds.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Featured Article: Outstanding Shares

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply